Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

Source:http://linkedlifedata.com/resource/pubmed/id/19687340

J. Clin. Oncol. 2009 Sep 20 27 27 4599-604

Download in:

View as

General Info

PMID
19687340